Hybio Pharmaceutical

Shenzhen Hybio Pharmaceutical Co., Ltd. is a national high-tech enterprise specializing in the integrated research, production, and sales of peptide drugs, and has always focused on the fields of peptide drugs and small nucleic acids. The company was listed on the Shenzhen Stock Exchange in 2011 (stock code: 300199), making it one of China's earlier listed peptide drug companies. The company has established the National-Local Joint Engineering Laboratory for Peptide Drugs, the National Public Experiment Center for Innovative Peptide Drugs, and the National Pilot Technology Platform for Peptide Drug Preparation, has undertaken multiple * projects, and has received national, provincial, and municipal honors and awards including the Second Prize of the National Technological Invention Award, the China Patent Excellence Award, National Intellectual Property Demonstration Enterprise, the Guangdong Provincial Science and Technology Award, and the Shenzhen Mayor's Award. Since its development, it has passed GMP certifications in China, the United States, the European Union, Brazil, Australia, South Korea, and others, opened up the upstream, midstream, and downstream vertical industry chain, and ensured full-chain control from raw materials to drugs. Hybio Pharmaceutical has always adhered to continuous innovation, taking becoming a * in the peptide industry as its vision and protecting life and health as its eternal mission.